A Study to Determine the Effectiveness and Tolerability of MK8141 in Patients With High Blood Pressure (MK-8141-006)
- Registration Number
- NCT00543413
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This study will evaluate the effectiveness and tolerability of MK8141 in lowering blood pressure in patients who have hypertension (high blood pressure).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
- You are 35 to 65 years of age
- In the past 14 days you have not been treated for hypertension
- In the past 14 days you have not taken more than 2 medications to treat high blood pressure
- You are a woman who is not able to have children or do not use birth control
Exclusion Criteria
- You are taking more than 2 medications to treat high blood pressure
- You have a history of a stroke, transient ischemic attack (TIA), heart attack, congestive heart failure, coronary artery bypass surgery
- You have Type 1 or 2 diabetes mellitus
- You have an active liver disease, gallbladder disease, or bowel disease
- You are HIV positive
- You have certain types of cancer
- You abuse drug or alcohol
- You have participated in another clinical study in last 4 weeks
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 MK8141 Arm 1: Drug 250 mg 2 MK8141 Arm 2: Drug 500 mg 3 Enalapril Arm 3: Active Comparator
- Primary Outcome Measures
Name Time Method To measure the tolerability and effectiveness of MK8141 in lowering 24-hour mean ambulatory blood pressure versus placebo after 4 weeks of treatment. after 4 weeks of treatment
- Secondary Outcome Measures
Name Time Method Compare MK8141 versus placebo in lowering 24-hour mean sitting blood pressure by ambulatory blood pressure monitoring and in lowering trough mean sitting diastolic and systolic blood pressure after 4 weeks of treatment. after 4 weeks of treatment